Head
neck
squamous
cell
carcinomas
(
HNSCC
)
sixth
common
malignancy
globally
,
increasing
proportion
oropharyngeal
HNSCCs
associated
human
papillomavirus
(
HPV
)
.

Patients
HPV-associated
tumours
markedly
improved
overall
disease-specific
survival
compared
HPV-negative
counterparts
treated
chemoradiation
.

Although
difference
outcomes
two
groups
clearly
established
,
mechanism
underlying
differences
remains
area
investigation
.

Data
preclinical
,
clinical
genomics
studies
started
suggest
increase
radio-sensitivity
HPV-positive
HNSCC
may
responsible
improved
outcomes
,
putative
mechanisms
review
.

The
Cancer
Genome
Atlas
others
recently
documented
multitude
molecular
differences
HPV-positive
HPV-negative
tumours
.

Preclinical
investigations
multiple
groups
explored
possible
mechanisms
increased
sensitivity
therapy
,
including
examining
differences
DNA
repair
,
hypoxia
immune
response
.

In
addition
differences
response
therapy
,
groups
started
investigate
phenotypic
differences
two
diseases
,
tumour
invasiveness
.

Finally
,
conclude
brief
review
ongoing
clinical
trials
attempting
de-escalate
treatment
minimise
long-term
toxicity
maintaining
cure
rates
.

New
insights
preclinical
genomic
studies
may
eventually
lead
personalised
treatment
paradigms
HPV-positive
patients
.

